Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.13 +0.19 (+0.76%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Tech Stocks Rise Ahead Of Key Earnings, Gold Smashes Records, Bitcoin Nears All-Time Highs: What's Driving Markets Tuesday?
Wall Street took a breather on Tuesday, with most major indices treading water, while tech stocks saw gains as investors braced for earnings reports from mega-cap companies. 
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
Pfizer Inc.’s Strong Q3 Performance: Beats Expectations With $1.06 EPS
Pfizer Inc. reported stellar third-quarter financial results, with revenues surging to $17.7 billion. 
Via Talk Markets
Pfizer Earnings Top Q3 Views; Pharma Giant Guides Higher
The drug giant comfortably beat estimates and raised full-year guidance. 
Via Investor's Business Daily
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions. 
Via Benzinga
Exposures COVID-19
US Stocks Likely To Open Weaker As Investors Eye Alphabet, AMD And Pfizer Earnings: Expert Says Won't Be 'Surprised' If Earnings Exceed Wall Street Expectations
U.S. stocks could see a weak opening on Tuesday after the averages registered a mixed last week. 
Via Benzinga
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer, Alphabet And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
The company's problems are no longer deniable. 
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
The market is overlooking the bigger picture for these three names. That means opportunity for you. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment
Knowing these will help you avoid making suboptimal investing decisions. 
Via The Motley Fool
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. 
Via Benzinga
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors. 
Via The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
There are more reasons to buy these stocks besides their high payouts. 
Via The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga
5 High-Yield Dividend Stocks to Buy Without Hesitation
These five dividend powerhouses offer yields above 4%. 
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth. 
Via Benzinga
Exposures Product Safety
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns. 
Via The Motley Fool
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets since the COVID-19 boom. 
Via Benzinga
Exposures COVID-19
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.